Ozal, Sadik AltanKupeli, AycaOzal, EceGurlu, Vuslat2024-06-122024-06-1220190004-27491678-2925https://doi.org/10.5935/0004-2749.20190040https://hdl.handle.net/20.500.14551/18919Purpose: To investigate changes in axial length after intravitreal dexamethasone implantation in patients with macular edema. Methods: We performed a prospective comparative study of 46 patients with unilateral macular edema, due to diabetic retinopathy, retinal vein occlusion, and non-infectious uveitis, who underwent dexamethasone implantation. The fellow eyes of the patients were considered the control group. The central macular thickness was measured by spectral-domain optical coherence tomography, and axial length was measured by IOLMaster 700 optical coherence biometry. We compared axial length and central macular thickness values within the groups. Results: In the study group, the baseline central macular thickness was 460.19 +/- 128.64 mu m, significantly decreasing to 324.00 +/- 79.84 mu m after dexamethasone implantation (p=0.000). No significant change in central macular thickness measurements was seen in the control group (p=0.244). In the study group, the baseline axial length was 23.16 +/- 0.68 mm, significantly increasing to 23.22 +/- 0.65 mm after dexamethasone implantation (p=0.039). However, the control group exhibited no significant change in axial length (p=0.123). Conclusions: In addition to significantly reducing central macular thickness measurements, intravitreal dexamethasone implantation also significantly changes optical biometry-based axial length measurements.en10.5935/0004-2749.20190040info:eu-repo/semantics/openAccessAxial Length, EyeDexamethasone/Administration & DosageIntravitreal Injections, Drug ImplantsMacular EdemaChamber Depth MeasurementsDiabetic Macular EdemaControlled-TrialCataractSeverityAccuracyTherapyArticle823195199Q4WOS:0004681236000062-s2.0-8506628539430810616Q3